Abstract Library

#4364 Single agent axitinib in the management of patients with progressive pheochromocytoma and paraganglioma

Introduction: Radiolabelled therapy with meta-iodobenzguanine (MIBG) and chemotherapy with a combination of cyclophosphamide, vincristine, and dacarbazine can help manage patients with metastatic pheochromocytoma and paraganglioma (mPPGL). The phase II FIRSTMAPPP study supports the use of the tyrosine kinase inhibitor sunitinib in these malignancies, with median progression-free survival values of 8.9 versus 3.6 months and overall response rates of 31% versus 8% for sunitinib versus placebo. The median duration of sunitinib therapy was 11 months. Concurrent with this study, we launched a single-arm trial to examine the activity of a similar tyrosine kinase inhibitor, axitinib.

Conference:

Presenting Author: Del Rivero J

Authors: Del Rivero J, Fojo T, Edgerly M, Pacak K, Figg W,

Keywords: PPGL, pheochromocytoma, paraganglioma, axitinib, TKI, tyrosinase kinase inhibitors,

#3044 Efficacy of Alkylating Agent Re-challenge after Therapeutic Pause in Metastatic Pancreatic Neuroendocrine Tumors (PanNET)

Introduction: Temozolomide (TMZ) and dacarbazine (DTIC) are alkylating agents (ALK) with antitumor efficacy in metastatic PanNET. Rechallenging ALK following prior efficacy is commonly performed but has not been evaluated.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: De Rycke O, Walter T, Perrier M, Hentic O, Lombard-Bohas C,

Keywords: alkylating agents, pancreatic NET, re-challenge, chemotherapy,

#2699 Dacarbazine- or Temozolomide-Based Chemotherapy in Metastatic Digestive Neuroendocrine Carcinomas in Post First-line Chemotherapy: A Retrospective Multicentric Study of the French Group of Endocrine Tumours (GTE)

Introduction: First-line chemotherapy in metastatic neuroendocrine carcinomas (NEC) is based on etoposide and platinum. However, there is no standard for second line treatment.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Walter T

Authors: Couronne T, Fine C, Hadoux J, Lecomte T, Lorcet M,

Keywords: neuroendocrine, poorly differentiated neuroendocrine tumour, neuroendocrine carcinoma, chemotherapy, temozolomide, dacarbazine,

#1828 5-Fluorouracile Plus Dacarbazine in Metastatic Digestive Neuroendoendocrine Tumors: Efficacy and Potential Biomarkers

Introduction: The 5-fluorouracile (5FU) + dacarbazine (DTIC) combination has been poorly evaluated in NET

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: de Mestier L

Authors: De Mestier L, Cros J, Hentic O, Legoux J, Muller N,

Keywords: chemotherapy, tumor response, tolerance, pfs,

#1537 Antitumor Efficacy of Temozolomide in Patients with Metastatic Pulmonary Carcinoids

Introduction: Temodal (TMZ) is an oral alternative to dacarbazine.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Bello Roufai D, Planchard D, Walter T, Berdelou A, Guigay J,

Keywords: pulmonary carcinoids, temozolomide, safety,